trial · primary record
Pumitamig
Non-small Cell Lung Cancer
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1580 |
| Primary completion | 2031-12 |
| Primary endpoint | Phase 2 - Occurrence of treatment-emergent adverse events (TEAE) (including Grade ≥3), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-emergent serious adverse events (SAE), and treatment-related treatment emergent SAEs |
| Registry ID | NCT06712316 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:23.538Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06712316
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Pumitamig · compound